Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Kidney Int ; 93(2): 482-490, 2018 02.
Article in English | MEDLINE | ID: mdl-28965746

ABSTRACT

HLA matching and mismatching, while inversely related, are not exact opposites. Here we determined the independent effects of HLA matching and mismatching on outcomes in deceased donor kidney transplant recipients. The United Network for Organ Sharing database (1995-2012) was utilized and analyzed for delayed graft function, one-year acute rejection, and death-censored graft survival using combined multivariable models including HLA matching and mismatching. Sensitivity analyses were performed using the subgroup of deceased donor kidney transplant patients after 2003 with more uniform HLA nomenclature and resampling analyses using bootstrapping on complete data available from 96,236 recipients. Individually, both HLA matching and mismatching showed significant associations with graft survival. Adjusting the model to take into account both matching and mismatching simultaneously, the degree of HLA mismatching lost significance while matching continued to have a significant prediction for delayed graft function, the one-year acute rejection rate, and graft survival. Sensitivity analyses and bootstrapping showed similar results for all studied outcomes. Thus, analysis of this large cohort demonstrates the apparent greater association of HLA matching over HLA mismatching on both early allograft events as well as graft survival. Future analyses should preferentially utilize HLA matching as a covariate over mismatching for accurately reflecting impact on graft outcomes.


Subject(s)
Delayed Graft Function/immunology , Graft Rejection/immunology , Graft Survival , HLA Antigens/immunology , Histocompatibility Testing , Histocompatibility , Kidney Transplantation , Tissue and Organ Procurement , Delayed Graft Function/mortality , Delayed Graft Function/prevention & control , Graft Rejection/mortality , Graft Rejection/prevention & control , Humans , Kidney Transplantation/adverse effects , Kidney Transplantation/mortality , Predictive Value of Tests , Protective Factors , Registries , Retrospective Studies , Risk Factors , Time Factors , Treatment Outcome , United States/epidemiology
2.
Clin Transplant ; 32(12): e13428, 2018 12.
Article in English | MEDLINE | ID: mdl-30338873

ABSTRACT

Simultaneous liver-kidney allocation protocols allocate dual organs based on a sustained eGFR of 30 mL/min or less. A 2017-UNOS update includes CKD3 as dual organ candidates but only when the listing eGFR is <30 mL/min while recommending a "safety net" for prioritized kidney listing post-LT. We retrospectively reviewed adult LTs examine whether the UNOS proposal captured the LT population at highest risk for developing post-LT ESRD. Among 290 LT recipients, 67 had pre-LT CKD3, 141 had AKI, of whom 47 required dialysis (<4 weeks). During follow-up, 25 (8.62%) developed ESRD, while 70 (24.1%) died. In adjusted Cox models, CKD3 had an independent association with post-LT ESRD (adjusted HR 4.8; P = 0.001), independent of AKI. Interestingly, CKD3 with listing GFR >30 mL/min was still significantly associated with post-LT ESRD. AKI was associated with reduced post-LT survival (adjusted HR 1.9; P = 0.02), albeit only in the first-year post-LT. Severe AKI-D was associated with post-LT ESRD and mortality. The safety net would have captured only 60% of all post-LT ESRD cases in our cohort. Pre-LT CKD3 was associated with increased risk of post-LT ESRD above the recommended cutoff for listing GFR. These findings, if generalizable in larger cohorts have important implications for dual organ allocation.


Subject(s)
End Stage Liver Disease/mortality , Graft Rejection/mortality , Graft Survival , Kidney Failure, Chronic/complications , Liver Transplantation/mortality , Postoperative Complications/mortality , Renal Insufficiency/complications , Aged , Case-Control Studies , End Stage Liver Disease/surgery , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/etiology , Graft Rejection/pathology , Humans , Kidney Function Tests , Liver Transplantation/adverse effects , Male , Middle Aged , Postoperative Complications/etiology , Postoperative Complications/pathology , Prognosis , Registries , Retrospective Studies , Risk Factors
3.
Drug Metab Dispos ; 45(4): 346-352, 2017 04.
Article in English | MEDLINE | ID: mdl-28153841

ABSTRACT

Cytochrome P450 2D6 (CYP2D6) is a major drug-metabolizing enzyme, but the factors governing transcriptional regulation of its expression remain poorly understood. Based on previous reports of small heterodimer partner (SHP) playing an important role as a transcriptional repressor of CYP2D6 expression, here we investigated how a known upstream regulator of SHP expression, namely cholestasis triggered by cholic acid (CA) feeding in mice, can lead to altered CYP2D6 expression. To this end, CYP2D6-humanized (Tg-CYP2D6) mice were fed with a CA-supplemented or control diet for 14 days, and hepatic expression of multiple genes was examined. Unexpectedly, CA feeding led to insignificant changes in SHP mRNA but also to significant (2.8-fold) decreases in SHP protein levels. In silico analysis of the SHP gene regulatory region revealed a putative binding site for a microRNA, miR-142-3p. Results from luciferase reporter assays suggest that miR-142-3p targets the SHP gene. Hepatic expression of miR-142-3p was significantly increased in CA-fed mice (∼5-fold), suggesting a potential role of miR-142-3p in the regulation of SHP expression in cholestasis. The decreased SHP protein levels were accompanied by increased expression and activity of CYP2D6 in the liver of CA-fed mice. These results suggest potential roles of differential hepatic levels of bile acids in the transcriptional regulation of CYP2D6 expression.


Subject(s)
Cholestasis/metabolism , Cytochrome P-450 CYP2D6/metabolism , Gene Expression Regulation , MicroRNAs/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Binding Sites , Cholestasis/chemically induced , Cholestasis/genetics , Cholic Acid/toxicity , Cytochrome P-450 CYP2D6/genetics , Disease Models, Animal , HEK293 Cells , Humans , Liver/enzymology , Liver/pathology , Male , Mice , Mice, Transgenic , Promoter Regions, Genetic , RNA, Messenger/metabolism
4.
Clin Transplant ; 31(5)2017 05.
Article in English | MEDLINE | ID: mdl-28267882

ABSTRACT

Belatacept is a non-nephrotoxic immunosuppressive agent, which may make it the ideal agent for patients with delayed or slow graft function on calcineurin inhibitors. There are limited data on conversion of patients to belatacept within 6 months of transplantation. Between January 2012 and December 2015, 16 patients were converted to belatacept for delayed or poor graft function (eGFR<30 mL/min/1.73 m2 , MDRD); three were HIV positive. Conversion protocols were analyzed in patients ≤4 months and 4-6 months post-transplantation. Mean serum creatinine levels after belatacept conversion were compared with preconversion levels. Patient survival was 100%, and graft survival was 88%. The mean creatinine fell from 3.9±1.82 mg/dL prebelatacept conversion to 2.1±1.1 mg/dL at 6 months and 1.9±0.47 mg/dL (median 1.8 mg/dL) at 12 months postconversion. There was no significant increased risk of rejection, infection, or malignancy. HIV parameters remained largely stable. Early conversion to belatacept in patients with DGF or slow graft function is safe and efficacious, in a single-center nonrandomized retrospective analysis.


Subject(s)
Abatacept/therapeutic use , Calcineurin Inhibitors/pharmacology , Graft Rejection/drug therapy , Graft Survival/drug effects , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/surgery , Kidney Transplantation/adverse effects , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/etiology , Humans , Kidney Function Tests , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors
5.
Vet Ophthalmol ; 20(1): 79-83, 2017 Jan.
Article in English | MEDLINE | ID: mdl-26945681

ABSTRACT

An 8-year-old mare was presented for investigation of a 1-month history of blepharospasm, eyelid swelling, corneal edema, and ocular discharge of the right eye (OD). Ophthalmic examination confirmed mucopurulent ocular discharge, conjunctival hyperemia, and a dry, dull appearance to the cornea OD. Schirmer tear test results confirmed an absence of tear production OD (0 mm/min) consistent with keratoconjunctivitis sicca. Treatment with topical 0.2% cyclosporine A resulted in an improvement in clinical signs. An episcleral cyclosporine A implant was placed under standing sedation 5 days after initial presentation. Re-examination 9 days post-operatively confirmed that the mare's tear production in the right eye had improved and no further clinical signs had been observed. Topical medications were gradually discontinued. Re-examinations performed up to 12 months postsurgery showed no recurrence of clinical signs and no adverse effects of the implant. To our knowledge, this is the first report of the use of a cyclosporine A implant in the management of KCS in a horse and highlights its potential as an effective, alternative therapy in the management of KCS in horses.


Subject(s)
Cyclosporine/therapeutic use , Drug Implants/therapeutic use , Horse Diseases/drug therapy , Keratoconjunctivitis Sicca/veterinary , Administration, Ophthalmic/veterinary , Animals , Cyclosporine/administration & dosage , Drug Implants/administration & dosage , Female , Horse Diseases/diagnosis , Horse Diseases/pathology , Horses , Keratoconjunctivitis Sicca/diagnosis , Keratoconjunctivitis Sicca/drug therapy , Keratoconjunctivitis Sicca/pathology , Sclera
6.
Transplant Proc ; 55(8): 1793-1798, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37487863

ABSTRACT

BACKGROUND: There is a paucity of evidence on the risk of donor-recipient transmission of the SARS-CoV-2 in solid organ transplant recipients. Initial impressions suggest non-lung solid organs may be safely transplanted from SARS-CoV-2-positive donors without risk of viral transmission. METHODS: We reviewed clinical results of transplants in which SARS-CoV-2-negative recipients received non-lung solid organs from SARS-CoV-2-positive donors at a single transplant center. No prisoners were used in this study, and participants were neither coerced nor paid. The manuscript was created in compliance with the Helsinki Congress and the Declaration of Istanbul. RESULTS: Between June 2021 and January 2023, we transplanted 26 solid organs, including 13 kidneys, 8 livers, 3 hearts, and 1 simultaneous heart and kidney, from 23 SARS-CoV-2-positive donors into 25 SARS-CoV-2 negative recipients. Two of the recipients had a positive SARS-CoV-2 real-time polymerase chain reaction after transplantation, but otherwise, patients had no SARS-CoV-2-related complications, and all patients to date are alive with excellent allograft function. CONCLUSION: Transplantation of non-lung solid organs from SARS-CoV-2-positive donors into uninfected recipients can be safely performed without adverse effects from SARS-CoV-2.


Subject(s)
COVID-19 , Organ Transplantation , Transplants , Humans , SARS-CoV-2 , Organ Transplantation/adverse effects , Tissue Donors , Transplant Recipients
8.
Drug Metab Lett ; 11(1): 68-72, 2017 11 17.
Article in English | MEDLINE | ID: mdl-28403802

ABSTRACT

BACKGROUND: Cytochrome P450 (CYP) 2D6 is a major drug-metabolizing enzyme, responsible for eliminating 25% of marketed drugs. We recently identified SHP as a negative regulator of CYP2D6 expression and showed that factors that alter SHP expression influence CYP2D6 expression. Fenofibrate, an agonist of peroxisome proliferator-activated receptor α(PPARα), has been previously reported to upregulate SHP expression in the mouse liver. The objective of this study was to determine whether fenofibrate decreases CYP2D6 expression via upregulating SHP expression. METHODS: CYP2D6-humanized transgenic mice were administered with fenofibrate (100 mg/kg/day intraperitoneally for 5 days) or vehicle control. Hepatic mRNA and protein expression levels of CYP2D6 and SHP were measured. RESULTS: Results showed that while mRNA levels of SHP did not differ between the groups, protein levels of SHP increased by 2-fold in fenofibrate-treated mice. Despite the increased SHP protein levels, CYP2D6 expression did not decrease at the mRNA or protein levels. Similar results were observed in human hepatocytes treated with fenofibrate. Results from transient transfection and promoter reporter assays indicate that PPARα can transactivate CYP2D6 promoter, suggesting that the lack of CYP2D6 downregulation by fenofibrate may be in part due to the activation of CYP2D6 promoter by PPARα. CONCLUSION: These results indicate that fenofibrate has minimal effects on CYP2D6 expression despite increased SHP expression.


Subject(s)
Cytochrome P-450 CYP2D6/metabolism , Fenofibrate/pharmacology , Hypolipidemic Agents/pharmacology , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Cytochrome P-450 CYP2D6/genetics , HEK293 Cells , Hepatocytes/metabolism , Humans , Male , Mice, Transgenic , PPAR alpha/metabolism , Promoter Regions, Genetic , RNA, Messenger/metabolism
9.
Clin Transpl ; 31: 69-78, 2015.
Article in English | MEDLINE | ID: mdl-28514569

ABSTRACT

Mount Sinai Hospital in New York has a long history in the field of organ transplantation. The first kidney transplant at Mount Sinai was performed in 1967 by the late Dr. Lewis Burrows and the first laparoscopic donor nephrectomy in New York was performed at Mount Sinai in 1996. Over 3000 kidney transplantations have been performed at Mount Sinai. In the early 1990s, the first hepatitis C virus (HCV) positive patient at Mount Sinai underwent a kidney transplant and the first kidney transplant in a patient with human immunodeficiency virus (HIV) in New York was performed at Mount Sinai in 2001. In general, these patients have done well after renal transplantation, with outcomes similar to those seen in non-infected patients. This chapter will describe the evolution of immunosuppressive regimens in HCV positive and HIV positive patients, and will describe the outcomes of kidney transplantation in these patients. Given the favorable outcomes, it is reasonable to continue to offer renal transplantation as a treatment for end stage renal disease patients with HCV and/or HIV.

10.
Comp Biochem Physiol C Toxicol Pharmacol ; 148(4): 305-14, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18577468

ABSTRACT

This study investigated the short-term (3 h) cadmium binding characteristics of the gills, as well as the influence of various water chemistry variables [calcium, magnesium, sodium, pH, alkalinity and dissolved organic carbon (DOC)] on short-term gill accumulation and acute toxicity of cadmium in juvenile freshwater rainbow trout. The cadmium binding pattern revealed two types of cadmium binding sites in the gill: (i) saturable high affinity sites operating at a low range of waterborne cadmium concentration, and (ii) non-saturable low affinity sites operating at a higher range of cadmium concentration. Among the water chemistry variables tested, only calcium and DOC significantly reduced both gill accumulation and toxicity of cadmium. Interestingly, alkalinity (15-90 mg L(-1) as CaCO(3)) did not influence the gill cadmium accumulation but a significant increase in toxicity was recorded at a higher alkalinity level (90 mg L(-1)). Affinity constants (log K) for binding of competing cations (Cd(2+) and Ca(2+)) to the biotic ligand and for binding of Cd(2+) to DOC were derived separately from the 3 h gill binding tests and the 96 h toxicity tests. In general, the values agreed well, indicating that both tests targeted the same population of high affinity binding sites, which are likely Ca(2+) uptake sites on the gills. These parameters were then incorporated into a geochemical speciation model (MINEQL+) to develop a biotic ligand model for predicting acute toxicity of cadmium in trout. The model predictions exhibited a good fit with the measured toxicity data except for high alkalinity and pH.


Subject(s)
Cadmium Chloride/toxicity , Fresh Water/chemistry , Gills/drug effects , Oncorhynchus mykiss/metabolism , Water Pollutants, Chemical/toxicity , Animals , Binding Sites , Cadmium Chloride/metabolism , Calcium/chemistry , Calcium Carbonate/chemistry , Dose-Response Relationship, Drug , Gills/metabolism , Hydrogen-Ion Concentration , Lethal Dose 50 , Ligands , Magnesium/chemistry , Organic Chemicals/chemistry , Reproducibility of Results , Sodium/chemistry , Time Factors , Water Pollutants, Chemical/metabolism
11.
Proc Natl Acad Sci U S A ; 100(18): 10213-8, 2003 Sep 02.
Article in English | MEDLINE | ID: mdl-12917488

ABSTRACT

The atp operon of alkaliphilic Bacillus pseudofirmus OF4, as in most prokaryotes, contains the eight structural genes for the F-ATPase (ATP synthase), which are preceded by an atpI gene that encodes a membrane protein of unknown function. A tenth gene, atpZ, has been found in this operon, which is upstream of and overlapping with atpI. Most Bacillus species, and some other bacteria, possess atpZ homologues. AtpZ is predicted to be a membrane protein with a hairpin topology, and was detected by Western analyses. Deletion of atpZ, atpI, or atpZI from B. pseudofirmus OF4 led to a requirement for a greatly increased concentration of Mg2+ for growth at pH 7.5. Either atpZ, atpI, or atpZI complemented the similar phenotype of a triple mutant of Salmonella typhimurium (MM281), which is deficient in Mg2+ uptake. atpZ and atpI, separately and together, increased the Mg2+-sensitive 45Ca2+ uptake by vesicles of an Escherichia coli mutant that is defective in Ca2+ and Na+ efflux. We hypothesize that AtpZ and AtpI, as homooligomers, and perhaps as heterooligomers, are Mg2+ transporter, Ca2+ transporter, or channel proteins. Such proteins could provide Mg2+, which is required by ATP synthase, and also support charge compensation, when the enzyme is functioning in the hydrolytic direction; e.g., during cytoplasmic pH regulation.


Subject(s)
Bacillus/genetics , Genes, Bacterial , Magnesium/metabolism , Operon , Proton-Translocating ATPases/genetics , Amino Acid Sequence , Bacillus/metabolism , Base Sequence , Calcium/metabolism , Hydrogen-Ion Concentration , Ion Transport , Molecular Sequence Data , Phenotype , Promoter Regions, Genetic , Transcription, Genetic
SELECTION OF CITATIONS
SEARCH DETAIL